# TRT Marketing Compliance for Men's Health Clinics: The Hypogonadism Labeling Line and the Anti-Aging Trap Testosterone replacement therapy (TRT) is a labeled prescription drug for classical hypogonadism, and TRT marketing has to be written against that label. Here is the compliance framework for men's health clinics offering TRT - distinct from broader BHRT - and the anti-aging claim trap that the FDA has explicitly warned against. By RegenCompliance Editorial (FDA/FTC compliance desk). Published 2026-05-19. Reading time 9 minutes. Canonical page: https://regencompliance.ai/blog/trt-marketing-compliance-mens-health Testosterone replacement therapy has an FDA-approved indication and a specific patient population behind it: classical hypogonadism, meaning men with low testosterone caused by identifiable disorders of the testes, pituitary gland, or brain. The FDA has explicitly warned about testosterone marketing for age-related low testosterone, and the labeled boxed warning includes cardiovascular language. Most men’s health clinic TRT copy is written as if the indication is feeling tired in your 40s. That gap is the entire compliance issue. This is a focused note on TRT specifically - the testosterone-replacement layer of the men’s-health-clinic offering - rather than broader hormone or bioidentical territory. For the wider HRT framework, see our companion post on [hormone replacement therapy marketing compliance](https://regencompliance.ai/blog/hormone-replacement-therapy-marketing-compliance). The 2015 FDA labeling change In 2015 the FDA required testosterone product labeling to clarify the approved use (classical hypogonadism due to identifiable medical conditions) and explicitly warned about marketing for age-related testosterone decline. A boxed warning addressing potential cardiovascular risks is part of that labeling story. Marketing copy that erases that distinction is operating outside the labeled indication. ## Pitfall 1: Selling age-related Low T as if it were the indication Low T is a marketing phrase, not a labeled indication. The FDA approved indication is hypogonadism due to specific medical conditions, not the normal age-related decline in testosterone that most men experience. See [high-risk phrases in healthcare marketing](https://regencompliance.ai/blog/banned-words-healthcare-marketing-2026) for the broader pattern of marketing shorthand that creates regulatory exposure. Marketing copy that conflates the two is one of the patterns the FDA called out in its 2014-2015 communications and continues to read as off-label promotion to the general public. Non-compliant “If you are a man over 40 with low energy, low libido, and brain fog, you probably have Low T - and TRT is the answer.” Compliant alternative “Testosterone replacement therapy is FDA-approved for men with low testosterone caused by specific medical conditions (classical hypogonadism). Age-related decline in testosterone is a different clinical picture; whether TRT is appropriate is determined through laboratory evaluation and clinical assessment, not through marketing copy.” Why: The bad version sells TRT to the entire over-40 male population using symptom shorthand for a labeled indication that requires lab-confirmed hypogonadism. That is the FDA-called-out pattern. ## Pitfall 2: Anti-aging and longevity framing Anti-aging language layered onto a testosterone prescription pulls TRT into the FTC anti-aging enforcement priority - on top of the FDA off-label-promotion concern. Reverse aging, regain your 25-year-old self, and restore youthful vitality are the exact phrasings that have driven adjacent FTC settlements in the hormone-product category. See the [FTC health claims standards](https://www.ftc.gov/business-guidance/advertising-marketing/health-claims) for the substantiation framework; our [NAD+ marketing compliance guide](https://regencompliance.ai/blog/nad-plus-marketing-compliance) covers the same anti-aging enforcement pattern in an adjacent category. Non-compliant “Restore the testosterone levels of your 25-year-old self - TRT is the science-backed way to reverse the effects of aging.” Compliant alternative “Testosterone replacement therapy can normalize testosterone levels in men with diagnosed hypogonadism. It is not marketed by this clinic as an anti-aging treatment or as a way to reverse aging.” Why: Reversing aging is a claim category the FTC has actively pursued in the hormone space; pairing it with a prescription drug that has a boxed warning is one of the highest-risk combinations in healthcare marketing. ## Pitfall 3: Cardiovascular-risk under-disclosure The labeling for testosterone products includes warnings addressing potential cardiovascular risk. Marketing copy that omits the risk picture entirely, or buries it in a 6-point disclaimer, is misaligned with what the label says. Honest risk disclosure is not optional in prescription-drug advertising; it is the regulatory baseline. Non-compliant “TRT is safe, effective, and life-changing. Side effects? Almost none.” Compliant alternative “Testosterone products carry labeled warnings addressing potential cardiovascular risk and other adverse effects. Our team reviews the risk profile, lab values, and individual health history with every prospective patient before prescribing.” Why: An almost-none framing on a prescription drug with a boxed warning is a near-perfect example of safety overstatement. The label exists; the marketing has to be consistent with it. ## Pitfall 4: Compounded testosterone equated with approved products Some clinics use compounded testosterone preparations rather than FDA-approved manufactured products (testosterone cypionate injections, AndroGel, Testopel pellets, etc.). Compounded preparations are not FDA-approved drug products under [FDA drug compounding laws](https://www.fda.gov/drugs/human-drug-compounding/human-drug-compounding-laws); the marketing has to distinguish them clearly. The compounded-vs- approved disclosure failure is the same pattern flagged in our [compounded GLP-1 post](https://regencompliance.ai/blog/glp-1-compounded-marketing-compliance-2026), and the rule rhymes. Non-compliant “Our pharmaceutical-grade testosterone pellets give you steady levels for months.” Compliant alternative “Our clinic uses compounded testosterone pellets prepared by a state-licensed compounding pharmacy under patient-specific prescription, or FDA-approved testosterone cypionate injections (as clinically appropriate). Compounded testosterone preparations are not FDA-approved drug products and are not interchangeable with approved products.” Why: Pharmaceutical-grade is a marketing term, not an FDA term. If the product is compounded, say so. If it is an approved product, name it. Compliant copy is specific. ## Pitfall 5: Testimonials presented as typical outcomes TRT testimonials tend toward dramatic results. Under the [FTC Endorsement Guides](https://www.ftc.gov/business-guidance/resources/ftcs-endorsement-guides-what-people-are-asking) 2023 update - see our [2023 Endorsement Guides overview](https://regencompliance.ai/blog/ftc-endorsement-guides-2023-update) - testimonials presented as representative outcomes either have to be supported by typical-experience evidence or paired with clear atypical-result disclosure, plus material-connection disclosure if the patient was incentivized. Non-compliant “I lost 40 lbs and feel 25 again on TRT. (typical patient result)” Compliant alternative “One patient described meaningful improvement in energy and body composition after starting TRT under clinical supervision. Individual responses vary; outcomes depend on baseline labs, adherence, lifestyle factors, and individual physiology, and are not predictive of yours.” Why: The bad version makes a single dramatic outcome a typical-experience claim. The Endorsement Guides 2023 update closed the gap around this pattern; clear-and-conspicuous typical-experience or atypical-result framing is the FTC baseline expectation. ## Do and don’t at a glance - **Do** describe TRT as a prescription therapy for men with diagnosed hypogonadism, confirmed by lab evaluation. - **Do** disclose the labeled risk picture (cardiovascular warnings, other adverse effects) in lead-level copy. - **Do** distinguish compounded testosterone preparations from FDA-approved manufactured products by name. - **Don’t** use Low T as a synonym for the labeled indication; the label says hypogonadism due to specific medical conditions, not normal age-related decline. - **Don’t** layer anti-aging or longevity framing on top of a prescription with a boxed warning. - **Don’t** present individual testimonials as typical outcomes without typical-experience evidence or atypical-result disclosure. ## TRT is not BHRT One quick clarification: testosterone replacement therapy for men is a distinct conversation from broader bioidentical hormone therapy, which more often refers to compounded estrogen/progesterone preparations marketed to women. The FDA position on compounded BHRT, the North American Menopause Society guidance, and the women’s-health marketing patterns are a separate stack. Don’t conflate the two in clinic copy - the rules and the risks are different. TRT rules in the scanner RegenCompliance flags off-label Low T promotion, anti-aging and longevity layering on TRT, cardiovascular-risk under- disclosure, compounded-vs-approved confusion, and typical- experience testimonial framing on testosterone marketing. If you run a men’s health clinic, pre-publish scanning catches these before a regulator or platform does. [Apply for the founder beta](https://regencompliance.ai/apply) or see the full [modality coverage list](https://regencompliance.ai/coverage). ## Adjacent reading Men’s health clinics frequently offer ketamine-adjacent mental-health services or refer to ketamine partners for mood and PTSD work. The compliance patterns are different but the off-label promotion frame is shared. See our [ketamine clinic marketing compliance guide](https://regencompliance.ai/blog/ketamine-clinic-marketing-compliance-guide) for the rhyme. Key Takeaways - TRT is FDA-approved for classical hypogonadism due to specific medical conditions; Low T as a synonym for age-related decline is the FDA-called-out off-label promotion pattern. - Testosterone product labeling includes warnings addressing potential cardiovascular risk; safety-overstatement and almost-no-side-effects framing is misaligned with the label. - Anti-aging and longevity framing applied to TRT layers the FTC anti-aging enforcement priority on top of the FDA off-label issue - one of the highest-risk combinations in healthcare marketing. - Compounded testosterone preparations are not FDA-approved drug products; compliance copy names the product and pathway specifically rather than using pharmaceutical-grade or similar marketing language. - Testimonial framing under the 2023 FTC Endorsement Guides update requires typical-experience evidence or clear atypical-result disclosure - dramatic single-patient outcomes presented as typical are the recurring pattern. --- RegenCompliance is FDA/FTC compliance scanning software for healthcare marketing, operated by Regen Portal LLC. Educational compliance tool, not legal advice. Not affiliated with the FDA or FTC. Contact: support@regencompliance.ai. Full site index for AI agents: https://regencompliance.ai/llms.txt